株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

女性不妊症:パイプライン製品の分析

Women Infertility - Pipeline Review, H1 2017

発行 Global Markets Direct 商品コード 264088
出版日 ページ情報 英文 190 Pages
即納可能
価格
本日の銀行送金レート: 1USD=112.55円で換算しております。
Back to Top
女性不妊症:パイプライン製品の分析 Women Infertility - Pipeline Review, H1 2017
出版日: 2017年03月31日 ページ情報: 英文 190 Pages
概要

女性不妊症とは、避妊をしていないのに1年間にわたり妊娠できない状態であり、女性不妊症には卵管の損傷、ホルモン要因、子宮頸および子宮の要因、原因が分からないもの、など数多くの因子があるとされています。

当レポートでは、女性不妊症に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

目次

イントロダクション

女性不妊症の概要

治療薬の開発

  • パイプライン製品:概要
  • 企業別治療薬
  • 大学/研究機関別治療薬
  • 開発中の製品:企業別
  • 調査中の製品:大学/研究機関別

治療薬の評価

  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

治療薬の開発に従事している企業

  • 4P Therapeutics LLC
  • AbbVie Inc
  • Addex Therapeutics Ltd
  • AlphaMab Co Ltd
  • APAvadis Biotechnologies Srl
  • ASKA Pharmaceutical Co Ltd
  • アステラス製薬
  • Bayer AG
  • Dong-A Socio Holdings Co Ltd
  • Dongkook Pharmaceutical Co Ltd
  • ElexoPharm GmbH
  • EndoCeutics Inc
  • Enteris BioPharma Inc
  • Evotec AG
  • Ferring International Center SA
  • Forendo Pharma Ltd
  • Glycotope GmbH
  • Isifer AB
  • キッセイ薬品工業
  • Lipicard Technologies Ltd
  • Livzon Pharmaceutical Group Inc
  • Luye Pharma Group Ltd
  • Merck & Co Inc
  • Navya Biologicals Pvt Ltd
  • 日本新薬
  • Nora Therapeutics Inc
  • ObsEva SA
  • Ogeda SA
  • Orphagen Pharmaceuticals Inc
  • Pangen Biotech Inc.
  • Pantec Biosolutions AG
  • PharmaEssentia Corp
  • Philogen SpA
  • Repros Therapeutics Inc
  • Richter Gedeon Nyrt
  • SK Chemicals Co Ltd
  • 武田薬品工業
  • TocopheRx Inc
  • ValiRx Plc
  • Viramal Ltd
  • Zydus Cadila Healthcare Ltd

薬剤のプロファイル

休止中のプロジェクト

開発が中止された製品

製品開発のマイルストーン

  • 最新ニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC9150IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Women Infertility - Pipeline Review, H1 2017, provides an overview of the Women Infertility (Women's Health) pipeline landscape.

Infertility is the inability to get pregnant after a year of unprotected intercourse. Female infertility can be also be caused by a number of factors, which include damage to fallopian tubes, hormonal causes, cervical causes, uterine causes, unexplained infertility. Treatment depends on the cause of infertility.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Women Infertility - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Women Infertility (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Women Infertility (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Women Infertility and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 5, 14, 14, 1, 28, 10 and 3 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 2, 6 and 3 molecules, respectively.

Women Infertility (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Women Infertility (Women's Health).
  • The pipeline guide reviews pipeline therapeutics for Women Infertility (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Women Infertility (Women's Health) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Women Infertility (Women's Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Women Infertility (Women's Health)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Women Infertility (Women's Health).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Women Infertility (Women's Health) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Women Infertility - Overview
    • Women Infertility - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Women Infertility - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Women Infertility - Companies Involved in Therapeutics Development
    • 4P Therapeutics LLC
    • AbbVie Inc
    • Addex Therapeutics Ltd
    • AlphaMab Co Ltd
    • APAvadis Biotechnologies Srl
    • ASKA Pharmaceutical Co Ltd
    • Astellas Pharma Inc
    • Bayer AG
    • Dong-A Socio Holdings Co Ltd
    • Dongkook Pharmaceutical Co Ltd
    • ElexoPharm GmbH
    • EndoCeutics Inc
    • Enteris BioPharma Inc
    • Evotec AG
    • Ferring International Center SA
    • Forendo Pharma Ltd
    • Glycotope GmbH
    • Isifer AB
    • Kissei Pharmaceutical Co Ltd
    • Lipicard Technologies Ltd
    • Livzon Pharmaceutical Group Inc
    • Luye Pharma Group Ltd
    • Merck & Co Inc
    • Navya Biologicals Pvt Ltd
    • Nippon Shinyaku Co Ltd
    • Nora Therapeutics Inc
    • ObsEva SA
    • Ogeda SA
    • Orphagen Pharmaceuticals Inc
    • Pangen Biotech Inc.
    • Pantec Biosolutions AG
    • PharmaEssentia Corp
    • Philogen SpA
    • Repros Therapeutics Inc
    • Richter Gedeon Nyrt
    • SK Chemicals Co Ltd
    • Takeda Pharmaceutical Company Ltd
    • TocopheRx Inc
    • ValiRx Plc
    • Viramal Ltd
    • Zydus Cadila Healthcare Ltd
  • Women Infertility - Drug Profiles
    • acolbifene hydrochloride + GnRH Agonist + prasterone - Drug Profile
    • ADX-68692 - Drug Profile
    • AKP-501 - Drug Profile
    • ASP-1707 - Drug Profile
    • barusiban - Drug Profile
    • BAY-1128688 - Drug Profile
    • BAY-1158061 - Drug Profile
    • Biosimilar 2 for Diabetes, Infertility and Rheumatoid Arthritis - Drug Profile
    • Biosimilar 5 for Infertility and Oncology - Drug Profile
    • Biosimilar 6 for Infertility, Oncology and Immunology - Drug Profile
    • Biosimilar 7 for Infertility, Immunology, Infectious Disease and Oncology - Drug Profile
    • choriogonadotropin alfa biosimilar - Drug Profile
    • choriogonadotropin alfa biosimilar - Drug Profile
    • danazol - Drug Profile
    • Drug 1 for Endometriosis - Drug Profile
    • Drug 2 for Endometriosis - Drug Profile
    • Drug 3 for Endometriosis - Drug Profile
    • Drug 4 for Endometriosis - Drug Profile
    • Drug 5 for Endometriosis - Drug Profile
    • Drug to Antagonize P2X3 for Endometriosis - Drug Profile
    • Drug to Inhibit C-Jun for Endometriosis - Drug Profile
    • Drug to Inhibit Interferon Gamma for Metabolic Disorders and Women's Health - Drug Profile
    • Drugs for Endometriosis and Uterine Fibroids - Drug Profile
    • EC-313 - Drug Profile
    • elagolix sodium - Drug Profile
    • EVE-104 - Drug Profile
    • FE-999310 - Drug Profile
    • fezolinetant - Drug Profile
    • follicle stimulating hormone biosimilar - Drug Profile
    • follitropin alfa biosimilar - Drug Profile
    • follitropin alfa biosimilar - Drug Profile
    • follitropin alfa biosimilar - Drug Profile
    • follitropin delta - Drug Profile
    • FP-5677 - Drug Profile
    • FSH-GEX - Drug Profile
    • goserelin biosimilar - Drug Profile
    • goserelin ER - Drug Profile
    • Isifera - Drug Profile
    • kisspeptin-54 - Drug Profile
    • KLH-2109 - Drug Profile
    • KN-015 - Drug Profile
    • leuprolide acetate - Drug Profile
    • LM-001 - Drug Profile
    • LM-002 - Drug Profile
    • LT-6121 - Drug Profile
    • menotropins - Drug Profile
    • MIA-602 - Drug Profile
    • MK-8389 - Drug Profile
    • Monoclonal Antibody Conjugate to Agonize FSH Receptor for Women Infertility - Drug Profile
    • NAV-013 - Drug Profile
    • NS-580 - Drug Profile
    • NT-100 - Drug Profile
    • OBE-001 - Drug Profile
    • PEG-FSH - Drug Profile
    • Peptide to Agonize FSH Receptor for Women Infertility - Drug Profile
    • Peptides for Endometriosis and Hepatic Tumor - Drug Profile
    • Peptides to Inhibit Aminopeptidase A for Endometriosis, Neuroblastoma and Hepatic (Liver) Tumor - Drug Profile
    • PGL-1001 - Drug Profile
    • PGL-2001 - Drug Profile
    • progesterone - Drug Profile
    • Recombinant Protein for Endometriosis, Ovarian Hyperstimulation Syndrome and Polycystic Ovarian Syndrome - Drug Profile
    • relugolix - Drug Profile
    • SKI-2670 - Drug Profile
    • Small Molecule to Antagonize FSH Receptor and LH Receptor for Women's Health - Drug Profile
    • Small Molecules for Female Infertility - Drug Profile
    • Small Molecules to Antagonize GnRH for Endometriosis, Male Health, Uterine Fibroids and Oncology - Drug Profile
    • Small Molecules to Antagonize Prostanoid EP2 and EP4 Receptors for Endometriosis - Drug Profile
    • Small Molecules to Antagonize SF-1 for Cushing Disease, Endometriosis and Oncology - Drug Profile
    • Small Molecules to Inhibit 17 Beta-HSD1 for Endometriosis - Drug Profile
    • Small Molecules to Inhibit 17 Beta-Hydroxysteroid Dehydrogenase Type1 for Endometriosis and Estrogen Dependent Cancers - Drug Profile
    • Small Molecules to Inhibit CD147 for Immunology, Oncology, Endometriosis and Arthritis - Drug Profile
    • SR-16234 - Drug Profile
    • STI-2833 - Drug Profile
    • Synthetic Peptide to Antagonize GPR54 for Womens Health, Male Health and Oncology - Drug Profile
    • TAK-448 - Drug Profile
    • telapristone acetate - Drug Profile
    • Tetravil - Drug Profile
    • TOP-001 - Drug Profile
    • TOP-002 - Drug Profile
    • triptorelin - Drug Profile
    • triptorelin acetate ER - Drug Profile
    • triptorelin biosimilar - Drug Profile
    • VAL-201 - Drug Profile
    • VAL-301 - Drug Profile
    • vilaprisan - Drug Profile
    • VPE-001 - Drug Profile
    • VPEA-004 - Drug Profile
  • Women Infertility - Dormant Projects
  • Women Infertility - Discontinued Products
  • Women Infertility - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Women Infertility, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Women Infertility - Pipeline by 4P Therapeutics LLC, H1 2017
  • Women Infertility - Pipeline by AbbVie Inc, H1 2017
  • Women Infertility - Pipeline by Addex Therapeutics Ltd, H1 2017
  • Women Infertility - Pipeline by AlphaMab Co Ltd, H1 2017
  • Women Infertility - Pipeline by APAvadis Biotechnologies Srl, H1 2017
  • Women Infertility - Pipeline by ASKA Pharmaceutical Co Ltd, H1 2017
  • Women Infertility - Pipeline by Astellas Pharma Inc, H1 2017
  • Women Infertility - Pipeline by Bayer AG, H1 2017
  • Women Infertility - Pipeline by Dong-A Socio Holdings Co Ltd, H1 2017
  • Women Infertility - Pipeline by Dongkook Pharmaceutical Co Ltd, H1 2017
  • Women Infertility - Pipeline by ElexoPharm GmbH, H1 2017
  • Women Infertility - Pipeline by EndoCeutics Inc, H1 2017
  • Women Infertility - Pipeline by Enteris BioPharma Inc, H1 2017
  • Women Infertility - Pipeline by Evotec AG, H1 2017
  • Women Infertility - Pipeline by Ferring International Center SA, H1 2017
  • Women Infertility - Pipeline by Forendo Pharma Ltd, H1 2017
  • Women Infertility - Pipeline by Glycotope GmbH, H1 2017
  • Women Infertility - Pipeline by Isifer AB, H1 2017
  • Women Infertility - Pipeline by Kissei Pharmaceutical Co Ltd, H1 2017
  • Women Infertility - Pipeline by Lipicard Technologies Ltd, H1 2017
  • Women Infertility - Pipeline by Livzon Pharmaceutical Group Inc, H1 2017
  • Women Infertility - Pipeline by Luye Pharma Group Ltd, H1 2017
  • Women Infertility - Pipeline by Merck & Co Inc, H1 2017
  • Women Infertility - Pipeline by Navya Biologicals Pvt Ltd, H1 2017
  • Women Infertility - Pipeline by Nippon Shinyaku Co Ltd, H1 2017
  • Women Infertility - Pipeline by Nora Therapeutics Inc, H1 2017
  • Women Infertility - Pipeline by ObsEva SA, H1 2017
  • Women Infertility - Pipeline by Ogeda SA, H1 2017
  • Women Infertility - Pipeline by Orphagen Pharmaceuticals Inc, H1 2017
  • Women Infertility - Pipeline by Pangen Biotech Inc., H1 2017
  • Women Infertility - Pipeline by Pantec Biosolutions AG, H1 2017
  • Women Infertility - Pipeline by PharmaEssentia Corp, H1 2017
  • Women Infertility - Pipeline by Philogen SpA, H1 2017
  • Women Infertility - Pipeline by Repros Therapeutics Inc, H1 2017
  • Women Infertility - Pipeline by Richter Gedeon Nyrt, H1 2017
  • Women Infertility - Pipeline by SK Chemicals Co Ltd, H1 2017
  • Women Infertility - Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017
  • Women Infertility - Pipeline by TocopheRx Inc, H1 2017
  • Women Infertility - Pipeline by ValiRx Plc, H1 2017
  • Women Infertility - Pipeline by Viramal Ltd, H1 2017
  • Women Infertility - Pipeline by Zydus Cadila Healthcare Ltd, H1 2017
  • Women Infertility - Dormant Projects, H1 2017
  • Women Infertility - Dormant Projects, H1 2017 (Contd..1), H1 2017
  • Women Infertility - Dormant Projects, H1 2017 (Contd..2), H1 2017
  • Women Infertility - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Women Infertility, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top